Get access

Hypomethylating agents for adult patients with acute myeloid leukaemia

  • Protocol
  • Intervention

Authors

  • Kathrin Bauer,

    Corresponding author
    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    • Kathrin Bauer, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Kerpener Str. 62, Cologne, 50924, Germany. kathrin.bauer@uk-koeln.de.

    Search for more papers by this author
  • Franz Hutzschenreuter,

    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author
  • Ina Monsef,

    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author
  • Nicole Skoetz,

    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author
  • Karl-Anton Kreuzer,

    1. University Hospital of Cologne, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author
  • Andreas Engert

    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The main objective of this systematic review is to evaluate the role of hypomethylating agents (i.e. 5-Aza, DAC) for untreated and previously treated patients with AML. For this purpose we will critically, systematically, and statistically analyse the efficacy of hypomethylating agents compared to best supportive care/no treatment as well as to other agents/chemotherapy regimens with regard to overall survival (OS), treatment-related mortality (TRM), complete response rate (CR), progression-free survival, quality of life, and adverse events.